RxDoctor Payments Data

Michael Boyiadzis

Pittsburgh, PANPI 1255303343

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $100 of the $143 with a category attached, or 69.7%. Janssen Research & Development, LLC accounts for 69.7% of it on its own, with 1 other manufacturer making up the rest.

$143in general payments, 2019–2025

Across 2 payments — averaging $71.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$100
  • Servier Pharmaceuticals LLC$43
$1,098,197in research payments, 2019–2025

Across 50 payments — averaging $21,964 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$676K
  • Merck$266K
  • Astellas Pharma Global Development$123K
  • Boehringer Ingelheim International GmbH$34K
  • AbbVie$50

What the payments were for

  • Speaking & faculty fees$4330%
  • Food & beverage$10070%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →